Tibet Aim Pharm.Inc. (002826.SZ) has released its third quarter report for 2026.
For the first three quarters, the company achieved operating revenue of 562 million yuan, representing a year-on-year increase of 14.95%.
Net profit attributable to shareholders of the listed company stood at 99.359 million yuan, up 21.52% compared with the same period last year.
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 74.3366 million yuan, surging 86.09% year-on-year.
Basic earnings per share came in at 0.54 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments